Additional file 1 of Unbiased combination screening on repurposed drugs reveals synergistic potential of copanlisib and cerivastatin against chemoresistant high-grade serous ovarian cancer

Supplementary Material 1: Supplementary Table 1: Clinical characteristics of HGSOC patients providing ascites for PADC cultures. Supplementary Table 2: DSS of 593 compounds across OVCAR3, OVCAR4, and Kuramochi cell lines. Supplementary Table 3: Compounds included in the MuSIC screening library with corresponding single-drug Z-scores in OVCAR3 cells. Supplementary Table 4: List of Primary and secondary antibodies for WB. Supplementary Table 5: DSS of OC standard-of-care chemotherapy drugs across 5 HGSOC cell lines. Supplementary Table 6: DSS of 112 selected compounds across five HGSOC cell lines. Supplementary Table 7: Potent drug combinations identified at 0.5 µM across 4 HGSOC cell lines.